



Pfizer ApS
Lautrupvang 8
DK-2750 Ballerup
Tlf.: 44 20 11 00
Fax: 44 20 11 01
www.pfizer.dk
CVR.nr. 66351912

Hæmofilicenter: Børne Unge Klinikken, afsnit 5002
Rigshospitalet
Blegdamsvej 9
2100 København
Att.: Maj Friberg Birkedal

Ballerup, November 9, 2017

Agreement on support to development of a haemophilia patient school

Pfizer wishes to provide support to the development and implementation of a patient school for haemophilia patients and their families and has therefore entered into this Agreement with Rigshospitalet, department 5002 (hereafter referred to as the "Recipient").

The purpose of the activity is to provide patients and their families with more knowledge about haemophilia and a better understanding of how to manage the disease.

The agreement shall run from March 2018 until September 2019.

Pfizer's financial commitment in relation to this Agreement shall be DKK 423,500 excl. VAT. Pfizer wishes to support 50% of the expenses related to the honoraria for the project employed nurse, medical consultant assistance, field trip and materials. Pfizer will not provide any non-financial support.

Responsible persons at the Hospital

The donation will be given to the Recipient and is approved by Klinikchef Karen Vitting Andersen at Rigshospitalet, department 5002, on behalf of the Hospital.

Furthermore the support is approved by Karen Vitting Andersen who is responsible for the hospital account to which the funding is paid to.

Disclaimer

The Recipient will ensure that the donation is used solely for professional and scientific purposes in relation to the activity and undertakes that any surplus from the donation not used in accordance herewith will be refunded.

Upon request from Pfizer the Recipient must document that the support is spend in accordance with the above-mentioned.

Disclosure

This Agreement shall be publicly disclosed on Pfizer's webpage (www.pfizer.dk) when the Agreement is made and for a period of 2 years thereafter.

Data Privacy

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located

in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland are protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.

You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.


The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's Representations and Warranties (Appendix A).

By signing this Agreement the Recipient confirms to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spend in accordance with the above mentioned terms and conditions.

We kindly ask you to return the signed agreement before November 16, 2017.

Date: 9/11-2017

Signature of authorized signatory on behalf of Pfizer:



Name: Lisa Almén
Title: Country Brand Lead, Haemophilia
Pfizer Rare Diseases

Date: 9/11 2017

Signature of authorized signatory on behalf of Rigshospitalet



Name: Karen Vitting Andersen
Title: Klinikchef, BUK
Consultant, MD & Head of Department
Department of Paediatrics
and Adolescent Medicine 4072
The Juliane Marie Centre, Rigshospitalet
Copenhagen University Hospital
Blegdamsvej 9, DK-2100 Copenhagen
tel.: +4535454305, www.paediatric.rh.dk
mail: karen.vitting.andersen@regionh.dk

Appendix A - Representations and Warranties

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;
- 1.3 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and
- 1.4 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.

